posaconazole

Product introduction:

Posaconazole is a derivative of itraconazole. It was the second generation of triazole antifungal drugs listed in FDA in 2006. The trade name is noxafil, and phase III clinical trial is currently under way. The pharmacological effect is the same as that of azole drugs, but compared with itraconazole, it has a stronger inhibitory effect on sterol C14 demethylation, especially on Aspergillus.

Indication:

This product is suitable for mycoemia caused by Candida and Cryptococcus fungi, respiratory, digestive and urinary tract mycosis, peritonitis, meningitis, etc.

Chinese Name：	泊沙康唑
Synonymous：	Pcz
CAS：	171228-49-2
Molecular formula：	C₃₇H₄₂F₂N₈O₄
Molecular weight：	700.78
Appearance	White Solid
Storage	Sealed in dry ；moisture-proof

Properties

Posaconazole is used in patients with invasive aspergillosis refractory to amphotericin B or itraconazole or in patients who cannot tolerate treatment with these agents.It is clinically useful in the treatment of aspergillosis, zygomycosis and sickle cell disease, but also in the treatment of some fluconazole resistant Candida infections.

CAS No.

171228-49-2

Formula

C37H42F2N8O4

Molecular Mass

700.77700

Exact Mass

700.33000

PSA

115.70000

Logp

4.70320

IUPAC

4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one

Matter Classification

organic

Category

Melting Point

170-1720C

Density

1.36 g/cm3

Boiling Point

850.7ºC at 760 mmHg

Flash Point

468.3ºC

Appearance